Yves Girard

TL;DR: Etoricoxib represents a novel agent that selectively inhibits COX-2 with 106-fold selectivity in human whole blood assays in vitro and with the lowest potency of inhibition ofCOX-1 compared with other reported selective agents.

TL;DR: A series of novel substituted 2-cyanoquinolines have been synthesized and the structure activity relationships were evaluated with respect to their ability to inhibit the formation of leukotrienes via the 5-lipoxygenase enzyme.

TL;DR: Rabbits were immunized with leukotriene C4 coupled to thiolated keyhole limpet hemocyanin (KLH) by using 6-N-maleimidohexanoic acid as a spacer molecule and conditions were established to determine LTC4 levels in human plasma without loss of L TC4 during sample preparation and without the need for extraction procedures before the measurement of LTC 4.

TL;DR: The results suggest that the LTE4 precursors, LTC4 and LTD4, are important bronchoconstrictor mediators causing EARs after allergen inhalation.

TL;DR: 5- Chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine 33 was identified as the optimum compound in this series and observed to inhibit COX-2 activity by introducing a substituent at C5 of the central pyridine.